ANALISIS D-DIMER DAN CRP PADA PASIEN COVID-19 DENGAN KOMORBID DIABETES MELLITUS
Abstract
Background:Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) is a virus that attacks and causes respiratory problems. Patients with comorbid diabetes mellitus are in the high-risk category if they get infected with COVID-19, with a 50% risk of death compared to those without diabetes mellitus. In Covid-19 patients, coagulation disorders are often found, and D-Dimer examination and CRP levels for inflammatory processes must bechecked to assess the continuity of the coagulation process. Aims:This research aims to analyze D-dimer and CRP levels in confirmed Covid-19 patients with comorbid diabetes mellitus at the Jakarta Haji Hospital. Methods:The research is a cross-sectional research design. Data was taken from medical records of patients aged over 25 years who were treated with confirmed Covid-19 with comorbid diabetes mellitus at the Jakarta Haji Hospital for the period June 2021-September 2021 and obtained data for 80 people. Results:Patient characteristics for this research in the majority age group came from adults (25-55 years), as many as 45 people (56%), the sex group of the majority of male patients totalling 44 people (55%), and Blood Glucose Levels during with the largest group in the group that has levels of 200 300 mg/dl of 57 people (71%). Analysis of D-Dimer levels showed that 50 people (63%) had high values (> 5 ng/mL), while CRP levels showed that 55 people (69%) had high values (> 60 mg/dL). Conclusion:COVID-19 patients with comorbid Diabetes Mellitus have increased levels of D-Dimer and CRP with mean results are 7.0 ng/mL and 68.5 mg/dL.
Full Text:
PDFReferences
WHO. COVID-19 diagnostic testing in the context of international travel: scientific brief, 16 December 2020. World Health Organization; 2020.
Rhodes R. Justice and guidance for the COVID-19 pandemic. Am J Bioeth. 2020;20(7):163–6.
Humairo A, Pratiwi AY, Mariyam S, Hasanah N. Upaya Pencegahan Pemutusan Mata Rantai Penularan Virus Corona Di Yayasan Pondok Pesantren Al-Hanif Kota Tangerang Selatan. J Pengabdi Kpd Masy Kreasi Mhs Manaj. 2021;1(1):28–32.
Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J intensive care. 2020;8:1–11.
Yu B, Li X, Chen J, Ouyang M, Zhang H, Zhao X, et al. Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis. J Thromb Thrombolysis. 2020;50:548–57.
Moreno G, Carbonell R, Bodí M, Rodríguez A. Systematic review of the prognostic utility of D-dimer, disseminated intravascular coagulation, and anticoagulant therapy in COVID-19 critically ill patients. Med Intensiva (English Ed. 2021;45(1):42–55.
Long H, Nie L, Xiang X, Li H, Zhang X, Fu X, et al. D-dimer and prothrombin time are the significant indicators of severe COVID-19 and poor prognosis. Biomed Res Int. 2020;2020.
Herold T, Jurinovic V, Arnreich C, Lipworth BJ, Hellmuth JC, von Bergwelt-Baildon M, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol. 2020;146(1):128–36.
Ryoo SM, Han KS, Ahn S, Shin TG, Hwang SY, Chung SP, et al. The usefulness of C-reactive protein and procalcitonin to predict prognosis in septic shock patients: A multicenter prospective registry-based observational study. Sci Rep. 2019;9(1):1–8.
Ali N. Elevated level of C‐reactive protein may be an early marker to predict risk for severity of COVID‐19. J Med Virol. 2020;92(11):2409.
Bajgain KT, Badal S, Bajgain BB, Santana MJ. Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature. Am J Infect Control. 2021;49(2):238–46.
Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med. 2020;2:1069–76.
Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr Clin Res Rev. 2020;14(4):303–10.
Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, et al. COVID-19 and comorbidities: Deleterious impact on infected patients. J Infect Public Health. 2020;13(12):1833–9.
Aufar AF, Raharjo ST. Kegiatan relaksasi sebagai coping stress di masa pandemi COVID-19. J Kolaborasi Resolusi Konflik. 2020;2(2):157–63.
Wati L, Nugraheni DM, Ratnaningrum K, Novitasari A. C-REACTIVE PROTEIN BERKORELASI TERHADAP KADAR D-DIMER PASIEN COVID-19. Al-Iqra Med J J Berk Ilm Kedokt. 2022;5(1):1–9.
Nanda CCS, Indaryati S, Koerniawan D. DM Pengaruh Komorbid Hipertensi dan Diabetes Mellitus terhadap Kejadian COVID-19: Comorbid COVID-19. J Keperawatan Florence Nightingale. 2021;4(2):68–72.
Abdi A, Jalilian M, Sarbarzeh PA, Vlaisavljevic Z. Diabetes and COVID-19: A systematic review on the current evidences. Diabetes Res Clin Pract. 2020;166:108347.
Fauzia NS. Faktor Risiko Terjadinya Coronavirus Disease 2019 Pada Pasien Dengan Komorbid Diabetes Melitus. Arter J Ilmu Kesehat. 2021;2(4):105–12.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–4.
Iba T, Levy JH, Levi M, Thachil J. Coagulopathy in COVID‐19. J Thromb Haemost. 2020;18(9):2103–9.
Potempa LA, Rajab IM, Hart PC, Bordon J, Fernandez-Botran R. Insights into the use of C-reactive protein as a diagnostic index of disease severity in COVID-19 infections. Am J Trop Med Hyg. 2020;103(2):561.
Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect. 2020;50(4):332–4.
Pepys MB. C-reactive protein predicts outcome in COVID-19: is it also a therapeutic target? Eur Heart J. 2021;42(23):2280.
Sharifpour M, Rangaraju S, Liu M, Alabyad D, Nahab FB, Creel-Bulos CM, et al. C-Reactive protein as a prognostic indicator in hospitalized patients with COVID-19. PLoS One. 2020;15(11):e0242400.
DOI: https://doi.org/10.33992/meditory.v11i1.2484
Refbacks
- There are currently no refbacks.

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Address: Jl. Sanitasi No.1, Sidakarya, Denpasar Selatan, Kota Denpasar, Bali 80224 (0361) 710447